Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
Eli Lilly and Company
Kivu Bioscience Inc.
MOMA Therapeutics
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Coherus Oncology, Inc.
Conjupro Biotherapeutics, Inc.
Alterome Therapeutics, Inc.
IDEAYA Biosciences
Aptamer Sciences, Inc.
Erasca, Inc.
Novartis
Eli Lilly and Company
National Cancer Institute (NCI)
GlaxoSmithKline
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Institut Paoli-Calmettes
Orano Med LLC
Eli Lilly and Company
Tomsk National Research Medical Center of the Russian Academy of Sciences
Imugene Limited
I-Mab Biopharma US Limited
University of California, Davis
ViroMissile, Inc.
Pfizer
Pfizer
Tizona Therapeutics, Inc
ALX Oncology Inc.
Genentech, Inc.
Angiex, Inc.
NiKang Therapeutics, Inc.
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Prelude Therapeutics
General Oncology, Inc.
Kyowa Kirin Co., Ltd.
Zhejiang University
National Cancer Institute (NCI)